AI Article Synopsis
- * A study involving 781 untreated stage A CLL patients compared five different risk scoring methods to see which best predicted disease progression, also assessing the impact of including the IGHV2 subset as a poor prognostic factor.
- * All five risk scores performed similarly in identifying low to high-risk patients, with CLL-IPI showing the best results, and findings indicate that incorporating IGHV2 could enhance the accuracy of these risk assessments.
Article Abstract
Background: Overall, the prognosis of patients with chronic lymphocytic leukemia (CLL) in the early phase of the disease (Rai 0, Binet A) is favorable; some patients never require therapy. However, some patients require intervention shortly after diagnosis. In the past decade, several risk scores (RS) have been developed to predict disease progression, yet some patients are misclassified. On the other hand, IGHV subset 2 (IGHV2) predicts poor outcomes.
Methods: A retrospective and multicentric study was conducted to compare the accuracy of five different RS (IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno) to predict disease progression in 781 stage A previously untreated patients with CLL. As an exploratory analysis, it was further investigated whether the inclusion of the IGHV2 as a poor prognostic parameter improved the accuracy of RS.
Results: All the scores identified a similar group of patients with CLL in early stage with low-, intermediate-, and high-risk progression. Discrimination was high and similar in all RS (c-index = 0.74-0.79, area under the curve = 0.7-0.75), as well as calibration (p = .98) and parsimony, although CLL-IPI showed the best results (Akaike information criterion = 441). A total of 34.4% of patients were categorized within the same RS and concordance was at least moderate between RS.
Conclusion: Moreover, the results suggest that IGHV2 may improve the accuracy of RS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.35552 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of trimethylamine N-oxide and metabolites with kidney function decline in patients with chronic kidney disease.
Clin Nutr
December 2024
Division of Nephrology, Department of Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, and School of Medicine, Tzu Chi University, Hualien, Taiwan. Electronic address:
Background: Trimethylamine N-oxide (TMAO) is a gut microbial metabolite derived from dietary l-carnitine and choline. High plasma TMAO levels are associated with cardiovascular disease and overall mortality, but little is known about the associations of TMAO and related metabolites with the risk of kidney function decline among patients with chronic kidney disease (CKD).
Methods: We prospectively followed 152 nondialysis patients with CKD stages 3-5 and measured plasma TMAO and related metabolites (trimethylamine [TMA], choline, carnitine, and γ-butyrobetaine) via liquid chromatography‒mass spectrometry.
ALSUntangled #77: Psilocybin.
Amyotroph Lateral Scler Frontotemporal Degener
December 2024
Department of Neurology, Duke University, Durham, NC, USA.
ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis and inflammation.
View Article and Find Full Text PDFIdentifying PTAFR as a hub gene in atherosclerosis: implications for NETosis and disease progression.
Hum Genomics
December 2024
Precision Medicine Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Atherosclerosis (AS) is a major cause of cardiovascular diseases and neutrophil extracellular traps (NETs) may be actively involved in the development of atherosclerosis. Identifying key biomarkers in this process is essential for developing targeted treatments for AS.
Methods: We performed bioinformatics analysis using a NETosis-related gene (NRGs) set and three AS datasets (GSE100927, GSE21545, and GSE159677).
Inhibition of microRNA-660-5p decreases breast cancer progression through direct targeting of TMEM41B.
Hereditas
December 2024
Facultad de Ciencias Biológicas, Departamento de Biología Celular y Genética, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, México.
Background: Breast cancer is the most prevalent cancer among women worldwide. Most breast cancer-related deaths result from metastasis and drug resistance. Novel therapies are imperative for targeting metastatic and drug-resistant breast cancer cells.
View Article and Find Full Text PDFInfectious Agents and Cancer journal has recently launched a new collection of papers about "Point-of-Care (POC) for HPV-related genital cancers" putting together some interesting works on the accuracy of HPV tests for screening. This editorial initiative gave us the opportunity to reflect on the relations between accuracy measures, prevalence and characteristics of the tested population in the case of HPV-based screening. In screening test evaluation, we look at the clinical accuracy of the test as an intrinsic characteristic of the assay, which interacts with the characteristics of the population, the result being the screening performance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!